RxDoctor Payments Data

Alexis Black

Family · Luling, LANPI 1649943937

Payments from drug & device makers

$8,050in general payments, 2019–2025

Across 123 payments — averaging $65.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$939
  • Teva Pharmaceuticals USA, Inc.$607
  • Sanofi$482
  • E.r. Squibb & Sons, L.L.C.$429
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$396
  • Johnson & Johnson$394
  • plus $5K from 37 others

What the payments were for

  • Speaking & faculty fees$340%
  • Food & beverage$8,016100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,050 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$8,644
Medicare patients
65
Services billed
106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban169$169,131
EntrestoSacubitril/Valsartan125$111,492
XareltoRivaroxaban33$39,260
JardianceEmpagliflozin14$13,262
BrilintaTicagrelor15$8,438
Repatha SureclickEvolocumab15$7,946
Atorvastatin Calcium243$1,763
Metoprolol Succinate162$1,448
Cilostazol62$1,291
Losartan Potassium101$819
Hydralazine Hcl34$753
Amlodipine Besylate166$713
Furosemide199$675
Rosuvastatin Calcium71$670
ClopidogrelClopidogrel Bisulfate117$649

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$69$169,131169 claims
NovartisEntresto$193$111,492125 claims
Johnson & JohnsonXarelto$394$39,26033 claims
Boehringer IngelheimJardiance$125$13,26214 claims
AstraZenecaBrilinta$368$8,43815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.

Other family in Luling

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →